Department of Health and Social Care

eMed Healthcare UK promises continuity and expansion following successful acquisition of Babylon - marking a new era for digital-first primary care in the UK

Retrieved on: 
Thursday, October 19, 2023
Digital, Grady EMS, Star, Babylon Health, Health care, Health, American Medical Association, Psychiatry, EMS Healthcare, Acquisition, Digital technology, Care Quality Commission, NHS, Public sector, England, NHS England, Eye, Department of Health and Social Care, NHS Improvement, African, Patient, GP, Health insurance, Video game, Pharmaceutical industry, Nursing, Limited

LONDON, Oct. 19, 2023 /PRNewswire/ -- eMed Healthcare UK, Limited (an operating subsidiary of US digital healthcare company eMed) has acquired Babylon Healthcare Services Limited and certain assets belonging to Babylon Group Holdings Limited and Babylon Partners Limited ("Babylon"). eMed Healthcare UK will continue to provide Babylon's digital-first 24/7 primary care and expand services through eMed's remote chronic care management starting with a clinician-led weight management programme.

Key Points: 
  • LONDON, Oct. 19, 2023 /PRNewswire/ -- eMed Healthcare UK, Limited (an operating subsidiary of US digital healthcare company eMed) has acquired Babylon Healthcare Services Limited and certain assets belonging to Babylon Group Holdings Limited and Babylon Partners Limited ("Babylon").
  • eMed Healthcare UK will continue to provide Babylon's digital-first 24/7 primary care and expand services through eMed's remote chronic care management starting with a clinician-led weight management programme.
  • She added: "Our focus for eMed Healthcare UK will be clinical excellence, high quality care, customer service and redefining chronic care management.
  • eMed Healthcare UK aims to be one of the leading digital-first primary care services in the UK, providing high quality, accessible care for all.

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

Retrieved on: 
Thursday, September 14, 2023
Department of Health and Social Care, Infection, OCC, Social work, Idiopathic pulmonary fibrosis, US Foods, Partnership, Cystic Fibrosis Trust, University, Emphysema, IV, Trust, DSM-IV codes, Medical Research Council, Wellcome Trust, Respiratory disease, University Hospitals Cleveland Medical Center, Department of Engineering Science, University of Oxford, Cystic fibrosis, Inflammation, Oxford Sciences Enterprises, GTC, CFTR, AATD, MD, Patient, Diagnosis, OSE, Imperial College London, Pharmaceutical industry, Management, Medical device, Grifols, Circassia

AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).

Key Points: 
  • AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).
  • AlveoGene will also evaluate the potential of the InGenuiTy™ platform alongside other technologies to create a pipeline of novel inhaled gene therapies targeting other rare respiratory disease opportunities, such as lung surfactant deficiencies and idiopathic pulmonary fibrosis.
  • This will enable AlveoGene to rapidly advance our first candidate – AVG-001 a unique, inhaled gene therapy for AATD – towards clinical development.
  • AlveoGene is the culmination of a successful collaboration between leading researchers from top-ranked UK universities, via GTC, and we believe the company has the potential to become a leader in respiratory gene therapy.

Brainomix Partners with TIPAL Trial to Assess Its Novel IPF Biomarker in Lung Disease

Retrieved on: 
Friday, September 8, 2023
Social work, CT, Idiopathic disease, Idiopathic pulmonary fibrosis, Oxford, National Institute of Health Research and Development (Indonesia), NNUH, Scar, ILD, Public, FVC, Lansoprazole, Norfolk and Norwich University Hospital, Lung, Government, Fibrosis, Department of Health and Social Care, Vital capacity, High-resolution scheme, Patient, Spirometry, NHS foundation trust, Heartburn, WRV, NIHR, Diagnosis, AI, IPF, Royal Brompton Hospital, Medical imaging

OXFORD, England, Sept. 8, 2023 /PRNewswire/ -- Brainomix announced today that they will be partnering with the TIPAL trial group to run a sub-study to assess the efficacy of its groundbreaking e-Lung platform. The TIPAL trial, funded by the National Institute of Health Research (NIHR) and sponsored by the Norfolk and Norwich University Hospitals (NNUH) NHS Foundation Trust, is a placebo-controlled 52-week multi-centre study that is evaluating the impact of lansoprazole – a commonly prescribed medication for indigestion, heartburn and acid reflux – on patients with a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF). IPF is a condition marked by relentless decline in lung function, but with a variable disease trajectory.

Key Points: 
  • OXFORD, England, Sept. 8, 2023 /PRNewswire/ -- Brainomix announced today that they will be partnering with the TIPAL trial group to run a sub-study to assess the efficacy of its groundbreaking e-Lung platform.
  • IPF is a condition marked by relentless decline in lung function, but with a variable disease trajectory.
  • The 298 patients expected to be enrolled in the trial will perform home spirometry tests to measure their forced vital capacity (FVC).
  • Professor Andrew Wilson, TIPAL Chief Investigator, said "It is great to have the chance to incorporate the cutting-edge CT scanning technology developed by Brainomix into the TIPAL study.

Lucy Letby: child murder case highlights need to regulate managers and improve whistleblowing procedures

Retrieved on: 
Friday, August 25, 2023
Review, Department, Social work, Reputational damage, Nursing, Trust, Count, Common, Bullying, Death, Department of Health and Social Care, Hospital, Bristol, Police, Cheshire Constabulary, Comment, NHS trust, Infant, NHS, Health, SOSR, Countess of Chester Hospital baby deaths, British Medical Association, Legislation, Health insurance, Management, Pharmaceutical industry, Policy

Two medical consultants, Dr Stephen Brearey and Dr Ravi Jayaram, both raised concerns about unexplained infant deaths as early as July 2015.

Key Points: 
  • Two medical consultants, Dr Stephen Brearey and Dr Ravi Jayaram, both raised concerns about unexplained infant deaths as early as July 2015.
  • Common sense would dictate that if a senior doctor raised concerns with managers, even informally, it would be taken seriously.
  • This highlights an urgent need to change the structure of the NHS to ensure managers and executives are held to account for the decisions they make.

Refusal to act

    • In hospitals such as the Countess of Chester, most routine decisions are made by middle management.
    • Brearey and Jayaram suggested that executives were attempting to minimise any reputational damage to the unit and, by extension, the hospital.
    • The decisions of hospital executives will be investigated as part of a public inquiry.

Freedom to Speak Up

    • This is what led to the Freedom to Speak Up review, which investigated how organisations dealt with concerns raised by NHS staff.
    • The results of the report led to the Freedom to Speak Up policy, which provides guidance for NHS staff on how they can raise patient safety concerns.
    • A Freedom to Speak Up Guardian is also now present in every NHS Trust to ensure issues raised are responded to.
    • Even with the Freedom to Speak Up Policy, the British Medical Association reports that staff are still being victimised for raising concerns.
    • Clearly, the policy needs to be improved and legislation passed that would protect staff from dismissal if they do speak up.

Police forces across England plan to respond to fewer mental health calls -- here's why

Retrieved on: 
Tuesday, June 20, 2023
People, Gaps, Volunteering, Home Office, Department, Social work, Humberside Police, Vacuum, Royal college, Arrest, Emergency, Crime, Sussex Police, Humberside, Imale, National Suicide Prevention Week, Mental Health Act 1983, Mental health, Metropolitan Police, Research, COVID, Mental, Anthony Clare, Police Scotland, Motion, Department of Health and Social Care, IASP, Triage, Population, Patient, Risk, Police, Metropolitan, Time, Lifeline (crisis support service), Trauma, Death, Sussex Partnership NHS Foundation Trust, Safety, Mental Health Act, Legislation, Nursing, Private investigator, Residential care, Hospital, Meat

The Metropolitan Police Commissioner Mark Rowley has announced that the London police force is to attend fewer mental health emergencies.

Key Points: 
  • The Metropolitan Police Commissioner Mark Rowley has announced that the London police force is to attend fewer mental health emergencies.
  • As part of an approach called Right Care, Right Person, police officers will only respond to 999 mental health calls when there is an “immediate threat to life”.
  • For many years now there have been calls, from people both within the police and those experiencing mental health crises, for the police to have less of a role in mental health emergencies.
  • Under Section 136 of the Mental Health Act, police officers can detain someone if they believe that person’s mental health is causing an immediate risk to the person or others.

Emergency response

    • And in 2021/22, Mind noted that the equivalent of the population of a British town was picked up by the police in this way.
    • Yearly numbers of Section 136 detentions in England and Wales from 2017/18 to 2021/22: Scotland’s reform was prompted by similar rising numbers.
    • In 2019 four in every five 999 calls to Police Scotland were reportedly not about crime but vulnerability.

A traumatic experience

    • Police cells were never the right place for someone experiencing a mental health crisis.
    • This is as humiliating for the people being escorted as it is demoralising for the officers involved.
    • The idea behind Right Care, Right Person is that people in crisis be cared for by mental health professionals.
    • Since 2013, mental health nurses have joined police officers in street triage schemes, accompanying them on patrol to provide immediate mental health support to people.
    • Being frequently detained by the police – without proper, long-term mental health support – makes vulnerable people feel worse.
    • In the US – call the National Suicide Prevention Lifeline at 1-800-273-TALK (8255) or IMAlive at 1-800-784-2433.

Protecting privacy during a pandemic: our work on the UK’s Covid apps

Retrieved on: 
Tuesday, April 25, 2023
Technology, Department, Social work, Health Protection Scotland, NHS COVID-19, ICO, API, DHSC, Privacy, Government, Department of Health and Social Care, NI, Health, Mobile phone

He led our operational response to the pandemic and leads our stakeholder relationships with the health and care sector.

Key Points: 
  • He led our operational response to the pandemic and leads our stakeholder relationships with the health and care sector.
  • In practice, the majority of our work to protect people’s privacy rights has a far lower profile.
  • Our work with the Department of Health and Social Care and Welsh Government around the NHS Covid app is a prime example.
  • We’re pleased that our work, started in March 2020, has helped to protect millions of people across the UK.

Global Inhaled and Intranasal Products Contract Service Providers Market 2023: Sector to Reach $4.5 Billion by 2030 at a 8.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, April 3, 2023
Health, Pharmaceutical, COPD, Social work, GSK plc, Asthma, Inhalation, Inhaler, United States National Library of Medicine, COVID-19, Chapter Three, Chronic obstructive pulmonary disease, National library, Department of Health and Social Care, Patient, Growth, NIH, Pharmaceutical industry

Furthermore, one of the most important breakthroughs at the start of the new millennium was the regulatory approval and commercialization of Advair/Seretide (GlaxoSmithKline).

Key Points: 
  • Furthermore, one of the most important breakthroughs at the start of the new millennium was the regulatory approval and commercialization of Advair/Seretide (GlaxoSmithKline).
  • Hence, contributing to the growth of the inhaled & intranasal products contract service providers market.
  • Metered- dose inhalers (MDIs) segment dominated the market with a revenue share of 50.6% in 2022.
  • Inhaled and Intranasal Products Contract Service Providers Market Variables, Trends & Scope

John Edwards, Information Commissioner, delivers a keynote speech at IAPP Data Protection Intensive UK.

Retrieved on: 
Wednesday, March 15, 2023
British Medical Association, Driver, SARS, IAPP, Social work, GP, AI, Compliance, Algorithm, Civil Rights of Institutionalized Persons Act, Department, Cardiff University, Efficiency, NHS England, Collection, Parliament, California Community College Athletic Association, Classification, DPO, Muslims, Public sector, Safety, FOI, Philosophy, England, Rape, Review, Foot, Risk, Woman, NHS, Department of Health and Social Care, Eye, Confidentiality, Conference, Health, Innovation, ICO, DVLA, Record, Information privacy, Privacy, State, Instinct, Pension fund, Video game, Cryptocurrency, Medical device, Audit, Nursing, Risk management, Pharmaceutical industry, Locksmithing, Management, Experian, Ofqual
Key Points: 

Health Food Manufacturers' Association advises Vitamin D supplements may help safeguard against dietary deficiencies as food costs rise

Retrieved on: 
Thursday, March 9, 2023
Social work, Milk, Meat, Nutrition, Suggestion, HFMA, Cheese, Food, Risk, Nutrient, Government, Department of Health and Social Care, Vitamin D, Egg, Safety, Dietary supplement

The Government's roll-out of vitamin D supplementation to those in vulnerable categories, gave a clear signal that this nutrient is essential to wellbeing.

Key Points: 
  • The Government's roll-out of vitamin D supplementation to those in vulnerable categories, gave a clear signal that this nutrient is essential to wellbeing.
  • Health practitioners are keen to highlight the value of food supplements for those at risk of insufficient intake, especially when consumers are changing buying patterns, and adapting to rising food costs.
  • Foods with highest price increases include milk, cheese and eggs, all major contributors to vitamin D intakes in the British diet.
  • This is particularly true for vitamin D, for which milk, meat, fish, eggs and breakfast cereals are important dietary sources.

InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Retrieved on: 
Wednesday, December 28, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, HKEX, National Health Commission, Tafasitamab, Food, European Medicines Agency, National Medical Products Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Guangdong-Hong Kong-Macau Greater Bay Area, SSE, ASCT, DLBCL, NMPA, Immunotherapy, Patient, Lenalidomide, FDA, Department of Health and Social Care, EMA, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “The Hong Kong approval of tafasitamab and lenalidomide will not only provide access to eligible DLBCL patients in the region, but may also help patient access in the Greater Bay Area soon.
  • As part of this early access program, the first prescription of tafasitamab in combination with lenalidomide was filed in July at the Ruijin Hainan Hospital for an eligible DLBCL patient.
  • Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of relapsed or refractory DLBCL patients who are not eligible for autologous stem cell transplantation (ASCT).